Spyre Therapeutics, Inc.
corporate_fare Company Profile
Spyre Therapeutics, Inc. (NASDAQ:SYRE) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 34 items for SYRE at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-03, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for SYRE spans 10-Q, 8-K, 424B5, S-3ASR.
Recent high-impact activity:
- Spyre Posts $96.1M Q3 Loss, $1.1B Cash, Runway Into 2H 2029
- Spyre Posts $96.1M Q3 Loss, Expands HS Program With $1.5B Pro Forma Cash
- Spyre Therapeutics 8-K Confirms $350M Offering at $85/Share
- Spyre Prices $350M Public Offering at $85/Share, Adding $328.7M Net Proceeds
- Spyre Therapeutics Stock Slides 12% After $350M Offering Priced at $85
Financial Snapshot
Short Interest & Short Volume
12.69 days to coverFINRA reported short interest of 11,617,573 shares in SYRE as of the October 30, 2026 settlement, a 7.1% decrease from the prior period — about 12.7 days to cover at its recent average daily volume. On November 20, 2026, 53.8% of SYRE volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for SYRE, detected from its recent SEC filings · based on capital-structure filings through 2026-10-06.
Public Offering Priced at $85/Share · Net Proceeds of $328.7M
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →